Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets

The anti-α4β7 integrin antibody vedolizumab (VDZ) is successfully used for the treatment of inflammatory bowel diseases. However, only a subgroup of patients respond to therapy. VDZ is administered at a fixed dose, leading to a wide range of serum concentrations in patients. Previous work from our g...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Emily, Schweda, Anna, Ullrich, Karen A. -M., Voskens, Caroline, Atreya, Raja, Müller, Tanja M., Atreya, Imke, Neurath, Markus F., Zundler, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236604/
https://www.ncbi.nlm.nih.gov/pubmed/35575178
http://dx.doi.org/10.14309/ctg.0000000000000494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236604/
https://www.ncbi.nlm.nih.gov/pubmed/35575178
http://dx.doi.org/10.14309/ctg.0000000000000494

Ejemplares similares